1
|
Fernández A, Câmara N, Sierra E, Arbelo M, Bernaldo de Quirós Y, Jepson PD, Deaville R, Díaz-Delgado J, Suárez-Santana C, Castro A, Hernández JN, Godinho A. Cetacean Intracytoplasmic Eosinophilic Globules: A Cytomorphological, Histological, Histochemical, Immunohistochemical, and Proteomic Characterization. Animals (Basel) 2023; 13:2130. [PMID: 37443929 DOI: 10.3390/ani13132130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 06/16/2023] [Accepted: 06/19/2023] [Indexed: 07/15/2023] Open
Abstract
The nature, etiopathogenesis, and clinicopathologic relevance of the prevalent intracytoplasmic eosinophilic globules (IEGs) within hepatocytes of cetaceans are unknown. This study aims to evaluate the presence and characterize the IEGs in the hepatocytes of cetaceans using histochemical and immunohistochemical electron microscopy, Western blot, lectin histochemistry, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry techniques. A total of 95/115 (83%) animals (16 species) exhibited histologically evident intracytoplasmic round to oval, single to multiple, hyaline eosinophilic globules within the hepatocytes. These globules were largely PAS-positive, diastase resistant, and were immunopositive for fibrinogen (FB, 97%), albumin (Alb, 85%), and α1-antitrypsine (A1AT, 53%). The IEG positivity for FB and A1AT were correlated with live-stranding, hepatic congestion and a good nutritional status. The cetaceans lacking IEGs were consistently dead stranded and had poor body conditions. The IEGs in 36 bycaught cetaceans were, all except one, FB-positive and A1AT-negative. The IEGs exhibited morphologic and compositional variations at the ultrastructural level, suggesting various stages of development and/or etiopathogenesis(es). The glycocalyx analysis suggested an FB- and A1AT-glycosylation pattern variability between cetaceans and other animals. The proteomic analyses confirmed an association between the IEGs and acute phase proteins, suggesting a relationship between acute stress (i.e., bycatch), disease, and cellular protective mechanisms, allowing pathologists to correlate this morphological change using the acute hepatocytic cell response under certain stress conditions.
Collapse
Affiliation(s)
- Antonio Fernández
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
| | - Nakita Câmara
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
- The Oceanic Platform of the Canary Islands (PLOCAN), Carretera de Taliarte, s/n, 35200 Telde, Canary Islands, Spain
- Loro Parque Foundation, Avenida Loro Parque, s/n, 38400 Puerto de la Cruz, Canary Islands, Spain
| | - Eva Sierra
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
| | - Manuel Arbelo
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
| | - Yara Bernaldo de Quirós
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
| | - Paul D Jepson
- Zoological Society of London, Institute of Zoology, Regent's Park, London NW1 4RY, UK
| | - Rob Deaville
- Zoological Society of London, Institute of Zoology, Regent's Park, London NW1 4RY, UK
| | - Josué Díaz-Delgado
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
| | - Cristian Suárez-Santana
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
| | - Ayoze Castro
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
- The Oceanic Platform of the Canary Islands (PLOCAN), Carretera de Taliarte, s/n, 35200 Telde, Canary Islands, Spain
| | - Julia N Hernández
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
| | - Ana Godinho
- Veterinary Histology and Pathology, Atlantic Center for Cetacean Research, University Institute of Animal Health and Food Safety (IUSA), Veterinary School, University of Las Palmas de Gran Canaria, Calle Transmontaña, s/n, 35416 Arucas, Canary Islands, Spain
- Rua Central de Gandra, University Institute of Health Sciences (IUCS)-CESPU, 4585-116 Gandra, Portugal
| |
Collapse
|
5
|
Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VTG, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, Otagiri M, Maruyama T. Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models. J Pharmacol Exp Ther 2014; 352:244-57. [PMID: 25398242 DOI: 10.1124/jpet.114.219493] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Since reactive oxygen species (ROS) derived from Kupffer cells (KC), especially CD68(+) KC, play a key role in the induction of hepatic oxidative stress and injuries, we developed a polythiolated- and mannosylated human serum albumin (SH-Man-HSA), which functions as a novel nanoantioxidant for delivering thiol to CD68(+) KC. In vitro electron paramagnetic resonance coupled with pharmacokinetics and immunohistochemical studies showed that SH-Man-HSA possessed powerful radical-scavenging activity and rapidly and selectively delivered thiols to the liver via mannose receptor (CD206) on CD68(+) cells. SH-Man-HSA significantly improved the survival rate of concanavalin-A (Con-A)-treated mice. Moreover, SH-Man-HSA exhibited excellent hepatoprotective functions, not by decreasing tumor necrosis factor or interferon-γ production that is closely associated with Con-A-induced hepatitis, but by suppressing ROS production. Interestingly, the protective effect of SH-Man-HSA was superior to N-acetyl cysteine (NAC). This could be attributed to the difference in the inhibition of hepatic oxidative stress between the two antioxidants depending on their potential for thiol delivery to the liver. Similar results were also observed for acetaminophen (APAP)-induced hepatopathy models. Flow cytometric data further confirmed that an increase in F4/80(+)/ROS(+) cells was dramatically decreased by SH-Man-HSA. The administration of SH-Man-HSA at 4 hours following a Con-A or APAP injection also exhibited a profound hepatoprotective action against these hepatitis models, whereas this was not observed for NAC. It can be concluded therefore that SH-Man-HSA has great potential for use in a rescue therapy for hepatopathy as a nanoantioxidant because of its ability to efficiently and rapidly deliver thiols to CD68(+)/CD206(+) KC.
Collapse
Affiliation(s)
- Hitoshi Maeda
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Kenshiro Hirata
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Hiroshi Watanabe
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Yu Ishima
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Victor Tuan Giam Chuang
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Kazuaki Taguchi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Akihito Inatsu
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Manabu Kinoshita
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Motohiko Tanaka
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Yutaka Sasaki
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Masaki Otagiri
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Toru Maruyama
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| |
Collapse
|